{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:12:19Z","timestamp":1795209139981,"version":"4.10.3"},"reference-count":61,"publisher":"American Association for Cancer Research (AACR)","issue":"18","funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["CA217251"],"award-info":[{"award-number":["CA217251"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["CA221957"],"award-info":[{"award-number":["CA221957"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["CA264949"],"award-info":[{"award-number":["CA264949"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220460"],"award-info":[{"award-number":["RP220460"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>A subset of cancers across multiple histologies with predominantly poor outcomes use the alternative lengthening of telomeres (ALT) mechanism to maintain telomere length, which can be identified with robust biomarkers. ALT has been reported to be prevalent in high-risk neuroblastoma and certain sarcomas, and ALT cancers are a major clinical challenge that lack targeted therapeutic approaches. Here, we found ALT in a variety of pediatric and adult cancer histologies, including carcinomas. Patient-derived ALT cancer cell lines from neuroblastomas, sarcomas, and carcinomas were hypersensitive to the p53 reactivator eprenetapopt (APR-246) relative to telomerase-positive (TA+) models. Constitutive telomere damage signaling in ALT cells activated ataxia-telangiectasia mutated (ATM) kinase to phosphorylate p53, which resulted in selective ALT sensitivity to APR-246. Treatment with APR-246 combined with irinotecan achieved complete responses in mice xenografted with ALT neuroblastoma, rhabdomyosarcoma, and breast cancer and delayed tumor growth in ALT colon cancer xenografts, while the combination had limited efficacy in TA+ tumor models. A large number of adult and pediatric cancers present with the ALT phenotype, which confers a uniquely high sensitivity to reactivation of p53. These data support clinical evaluation of a combinatorial approach using APR-246 and irinotecan in ALT patients with cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This work demonstrates that constitutive activation of ATM in chemotherapy-refractory ALT cancer cells renders them hypersensitive to reactivation of p53 function by APR-246, indicating a potential strategy to overcome therapeutic resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-22-0125","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T13:51:50Z","timestamp":1660139510000},"page":"3345-3358","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Alternative Lengthening of Telomeres in Cancer Confers a Vulnerability to Reactivation of p53 Function"],"prefix":"10.1158","volume":"82","author":[{"given":"Shawn J.","family":"Macha","sequence":"first","affiliation":[{"name":"1Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."},{"name":"2Department of Cell Biology & Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2163-7049","authenticated-orcid":false,"given":"Balakrishna","family":"Koneru","sequence":"additional","affiliation":[{"name":"1Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."},{"name":"3Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-837X","authenticated-orcid":false,"given":"Trevor A.","family":"Burrow","sequence":"additional","affiliation":[{"name":"1Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1431-1806","authenticated-orcid":false,"given":"Charles","family":"Zhu","sequence":"additional","affiliation":[{"name":"1Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5355-1020","authenticated-orcid":false,"given":"Dzmitry","family":"Savitski","sequence":"additional","affiliation":[{"name":"1Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhshanda L.","family":"Rahman","sequence":"additional","affiliation":[{"name":"1Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."},{"name":"4Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine A.","family":"Ronaghan","sequence":"additional","affiliation":[{"name":"1Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."},{"name":"4Department of Surgery, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Nance","sequence":"additional","affiliation":[{"name":"1Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."},{"name":"3Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyn","family":"McCoy","sequence":"additional","affiliation":[{"name":"1Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."},{"name":"3Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-0841","authenticated-orcid":false,"given":"Cody","family":"Eslinger","sequence":"additional","affiliation":[{"name":"1Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2827-8536","authenticated-orcid":false,"given":"C. Patrick","family":"Reynolds","sequence":"additional","affiliation":[{"name":"1Cancer Center, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."},{"name":"2Department of Cell Biology & Biochemistry, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."},{"name":"3Department of Pediatrics, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"2025112417221448500_bib1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00001622-199601000-00012","article-title":"Telomerase activity in human cancer","volume":"8","author":"Shay","year":"1996","journal-title":"Curr Opin Oncol"},{"key":"2025112417221448500_bib2","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm1197-1271","article-title":"Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines","volume":"3","author":"Bryan","year":"1997","journal-title":"Nat Med"},{"key":"2025112417221448500_bib3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0959-437X(99)80014-8","article-title":"Telomere maintenance mechanisms and cellular immortalization","volume":"9","author":"Colgin","year":"1999","journal-title":"Curr Opin Genet Dev"},{"key":"2025112417221448500_bib4","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ajpath.2011.06.018","article-title":"Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes","volume":"179","author":"Heaphy","year":"2011","journal-title":"Am J Pathol"},{"key":"2025112417221448500_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41467-017-02602-0","article-title":"Integrative genomic and transcriptomic analysis of leiomyosarcoma","volume":"9","author":"Chudasama","year":"2018","journal-title":"Nat Commun"},{"key":"2025112417221448500_bib6","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1158\/0008-5472.CAN-19-3068","article-title":"Telomere maintenance mechanisms define clinical outcome in high-risk neuroblastoma","volume":"80","author":"Koneru","year":"2020","journal-title":"Cancer Res"},{"key":"2025112417221448500_bib7","doi-asserted-by":"crossref","first-page":"eabd5750","DOI":"10.1126\/scitranslmed.abd5750","article-title":"ALT neuroblastoma chemoresistance due to telomere dysfunction\u2013induced ATM activation is reversible with ATM inhibitor AZD0156","volume":"13","author":"Koneru","year":"2021","journal-title":"Sci Transl Med"},{"key":"2025112417221448500_bib8","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2013.10.020","article-title":"Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors","volume":"146","author":"Marinoni","year":"2014","journal-title":"Gastroenterology"},{"key":"2025112417221448500_bib9","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/IGC.0b013e31823ca017","article-title":"Prognostic value of alternative lengthening of telomeres-associated biomarkers in uterine sarcoma and uterine carcinosarcoma","volume":"22","author":"Lee","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"2025112417221448500_bib10","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/nature20099","article-title":"Break-induced telomere synthesis underlies alternative telomere maintenance","volume":"539","author":"Dilley","year":"2016","journal-title":"Nature"},{"key":"2025112417221448500_bib11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1126\/science.1257216","article-title":"Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors","volume":"347","author":"Flynn","year":"2015","journal-title":"Science"},{"key":"2025112417221448500_bib12","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1038\/s41467-019-08905-8","article-title":"G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma","volume":"10","author":"Wang","year":"2019","journal-title":"Nat Commun"},{"key":"2025112417221448500_bib13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","article-title":"The multiple mechanisms that regulate p53 activity and cell fate","volume":"20","author":"Hafner","year":"2019","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025112417221448500_bib14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrm4007","article-title":"p53 in survival, death and metabolic health: a lifeguard with a licence to kill","volume":"16","author":"Kruiswijk","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2025112417221448500_bib15","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature12912","article-title":"Discovery and saturation analysis of cancer genes across 21 tumour types","volume":"505","author":"Lawrence","year":"2014","journal-title":"Nature"},{"key":"2025112417221448500_bib16","doi-asserted-by":"crossref","first-page":"e1002772","DOI":"10.1371\/journal.pgen.1002772","article-title":"Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway","volume":"8","author":"Lovejoy","year":"2012","journal-title":"PLoS Genet"},{"key":"2025112417221448500_bib17","doi-asserted-by":"crossref","first-page":"e1008039","DOI":"10.1371\/journal.pgen.1008039","article-title":"Loss of atrx cooperates with p53-deficiency to promote the development of sarcomas and other malignancies","volume":"15","author":"Oppel","year":"2019","journal-title":"PLoS Genet"},{"key":"2025112417221448500_bib18","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.celrep.2016.05.008","article-title":"Telomere replication stress induced by POT1 inactivation accelerates tumorigenesis","volume":"15","author":"Pinzaru","year":"2016","journal-title":"Cell Rep"},{"key":"2025112417221448500_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0092-8674(00)80762-X","article-title":"p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis","volume":"97","author":"Chin","year":"1999","journal-title":"Cell"},{"key":"2025112417221448500_bib20","doi-asserted-by":"crossref","first-page":"14338","DOI":"10.1073\/pnas.94.26.14338","article-title":"Thermodynamic stability of wild-type and mutant p53 core domain","volume":"94","author":"Bullock","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025112417221448500_bib21","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.onc.1203434","article-title":"Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy","volume":"19","author":"Bullock","year":"2000","journal-title":"Oncogene"},{"key":"2025112417221448500_bib22","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025112417221448500_bib23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm0302-282","article-title":"Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound","volume":"8","author":"Bykov","year":"2002","journal-title":"Nat Med"},{"key":"2025112417221448500_bib24","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1038\/s41467-021-27142-6","article-title":"Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ)","volume":"12","author":"Degtjarik","year":"2021","journal-title":"Nat Commun"},{"key":"2025112417221448500_bib25","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41419-019-1997-z","article-title":"Correction: APR-246 reactivates mutant p53 by targeting cysteines 124 and 277","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis"},{"key":"2025112417221448500_bib26","doi-asserted-by":"crossref","first-page":"14844","DOI":"10.1038\/ncomms14844","article-title":"Inhibiting the system xC(-)\/glutathione axis selectively targets cancers with mutant-p53 accumulation","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"key":"2025112417221448500_bib27","doi-asserted-by":"crossref","first-page":"e10852","DOI":"10.15252\/emmm.201910852","article-title":"A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death","volume":"13","author":"Ceder","year":"2021","journal-title":"EMBO Mol Med"},{"key":"2025112417221448500_bib28","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1182\/blood-2014-01-548800","article-title":"PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH\/ROS balance","volume":"124","author":"Tessoulin","year":"2014","journal-title":"Blood"},{"key":"2025112417221448500_bib29","doi-asserted-by":"crossref","first-page":"e1794","DOI":"10.1038\/cddis.2015.143","article-title":"APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells","volume":"6","author":"Mohell","year":"2015","journal-title":"Cell Death Dis"},{"key":"2025112417221448500_bib30","first-page":"249","article-title":"APR-246 alone and in combination with a phosphatidylserine-targeting antibody inhibits lung metastasis of human triple-negative breast cancer cells in nude mice","volume":"11","author":"Liang","year":"2019","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2025112417221448500_bib31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3389\/fonc.2016.00021","article-title":"Targeting of mutant p53 and the cellular redox balance by APR-246 as a strategy for efficient cancer therapy","volume":"6","author":"Bykov","year":"2016","journal-title":"Front Oncol"},{"key":"2025112417221448500_bib32","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1038\/sj.onc.1204665","article-title":"Activation of p53 transcriptional activity requires ATM's kinase domain and multiple N-terminal serine residues of p53","volume":"20","author":"Turenne","year":"2001","journal-title":"Oncogene"},{"key":"2025112417221448500_bib33","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/BF00300234","article-title":"Determination of subcutaneous tumor size in athymic (nude) mice","volume":"24","author":"Tomayko","year":"1989","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025112417221448500_bib34","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1158\/1535-7163.MCT-16-0749","article-title":"Reactive oxygen species-mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies","volume":"16","author":"Makena","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2025112417221448500_bib35","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/pbc.22801","article-title":"National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing","volume":"56","author":"Kang","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"2025112417221448500_bib36","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/CAD.0000000000001020","article-title":"The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide + irinotecan against models of high-risk neuroblastoma","volume":"32","author":"Hindle","year":"2021","journal-title":"Anticancer Drugs"},{"key":"2025112417221448500_bib37","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/pbc.21078","article-title":"The pediatric preclinical testing program: description of models and early testing results","volume":"49","author":"Houghton","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"2025112417221448500_bib38","first-page":"173","article-title":"Evaluating response to antineoplastic drug combinations in tissue culture models","volume":"110","author":"Reynolds","year":"2005","journal-title":"Methods Mol Med"},{"key":"2025112417221448500_bib39","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1158\/0008-5472.CAN-04-2881","article-title":"Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies","volume":"65","author":"Fasching","year":"2005","journal-title":"Cancer Res"},{"key":"2025112417221448500_bib40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","article-title":"Next-generation characterization of the Cancer Cell Line Encyclopedia","volume":"569","author":"Ghandi","year":"2019","journal-title":"Nature"},{"key":"2025112417221448500_bib41","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1016\/j.celrep.2017.05.087","article-title":"Extensive proliferation of human cancer cells with ever-shorter telomeres","volume":"19","author":"Dagg","year":"2017","journal-title":"Cell Rep"},{"key":"2025112417221448500_bib42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1126\/science.1207313","article-title":"Altered telomeres in tumors with ATRX and DAXX mutations","volume":"333","author":"Heaphy","year":"2011","journal-title":"Science"},{"key":"2025112417221448500_bib43","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1038\/ncomms8538","article-title":"Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX","volume":"6","author":"Clynes","year":"2015","journal-title":"Nat Commun"},{"key":"2025112417221448500_bib44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejca.2015.12.002","article-title":"p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E\/K)BRAF melanoma to vemurafenib","volume":"55","author":"Krayem","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025112417221448500_bib45","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2025112417221448500_bib46","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.dnarep.2018.11.009","article-title":"Correcting errors in the BRCA1 warning system","volume":"73","author":"Liang","year":"2019","journal-title":"DNA Repair"},{"key":"2025112417221448500_bib47","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1126\/science.281.5383.1677","article-title":"Activation of the ATM kinase by ionizing radiation and phosphorylation of p53","volume":"281","author":"Canman","year":"1998","journal-title":"Science"},{"key":"2025112417221448500_bib48","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0092-8674(00)80932-0","article-title":"TRF2 protects human telomeres from end-to-end fusions","volume":"92","author":"van Steensel","year":"1998","journal-title":"Cell"},{"key":"2025112417221448500_bib49","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1126\/science.283.5406.1321","article-title":"p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2","volume":"283","author":"Karlseder","year":"1999","journal-title":"Science"},{"key":"2025112417221448500_bib50","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/nsmb.1725","article-title":"Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions","volume":"16","author":"Cesare","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"2025112417221448500_bib51","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.cell.2014.08.030","article-title":"Interchromosomal homology searches drive directional ALT telomere movement and synapsis","volume":"159","author":"Cho","year":"2014","journal-title":"Cell"},{"key":"2025112417221448500_bib52","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.celrep.2016.10.008","article-title":"Telomere-internal double-strand breaks are repaired by homologous recombination and PARP1\/Lig3-dependent end-joining","volume":"17","author":"Doksani","year":"2016","journal-title":"Cell Rep"},{"key":"2025112417221448500_bib53","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1172\/JCI6863","article-title":"Disruption of p53 in human cancer cells alters the responses to therapeutic agents","volume":"104","author":"Bunz","year":"1999","journal-title":"J Clin Invest"},{"key":"2025112417221448500_bib54","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13569-015-0035-x","article-title":"Fifteen years of irinotecan therapy for pediatric sarcoma: where to next?","volume":"5","author":"Wagner","year":"2015","journal-title":"Clin Sarcoma Res"},{"key":"2025112417221448500_bib55","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1200\/JCO.20.00203","article-title":"Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children's Oncology Group","volume":"38","author":"Mody","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025112417221448500_bib56","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.3748\/wjg.v21.i43.12234","article-title":"Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer","volume":"21","author":"Fujita","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2025112417221448500_bib57","doi-asserted-by":"crossref","first-page":"eaax2625","DOI":"10.1126\/scitranslmed.aax2625","article-title":"BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers","volume":"12","author":"Coussy","year":"2020","journal-title":"Sci Transl Med"},{"key":"2025112417221448500_bib58","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1038\/sj.onc.1202931","article-title":"p53-dependent apoptosis or growth arrest induced by different forms of radiation in U2OS cells: p21WAF1\/CIP1 repression in UV induced apoptosis","volume":"18","author":"Allan","year":"1999","journal-title":"Oncogene"},{"key":"2025112417221448500_bib59","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.celrep.2014.03.003","article-title":"Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma","volume":"7","author":"Chen","year":"2014","journal-title":"Cell Rep"},{"key":"2025112417221448500_bib60","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3390\/diagnostics11030496","article-title":"MDM2 amplified sarcomas: a literature review","volume":"11","author":"Sciot","year":"2021","journal-title":"Diagnostics"},{"key":"2025112417221448500_bib61","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ccell.2018.12.009","article-title":"Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers","volume":"35","author":"Ogiwara","year":"2019","journal-title":"Cancer Cell"}],"updated-by":[{"DOI":"10.1158\/0008-5472.can-25-0818","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000}}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/doi\/10.1158\/0008-5472.CAN-22-0125\/3187781\/can-22-0125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/82\/18\/3345\/3205160\/3345.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/82\/18\/3345\/3205160\/3345.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:23:11Z","timestamp":1764022991000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/82\/18\/3345\/709026\/Alternative-Lengthening-of-Telomeres-in-Cancer"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":61,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2022,8,10]]},"published-print":{"date-parts":[[2022,9,16]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-22-0125","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22432280","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22432283","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6514106.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22432283.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22432280.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6514106","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]}}}